Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:52 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation
NCT01035593 · Pharming Technologies B.V. · PHASE2 · withdrawn · last registry update 2012-02-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Recent improvements in clinical practice have reduced the apparent incidence of AMR in renal transplantation.” | – | Registry record, Pharming Technologies B.V. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SERPING1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2013-01-31Results posted on the registry: Pharming Technologies B.V., Recombinant Human C1 Inhibitor (NCT00851409)
- 2013-01-11Phase 3 first posted: Radboud University Medical Center, C1-esterase inhibitor + Endotoxin (NCT01766414)
- 2013-01-04Results posted on the registry: Shire, CINRYZE with rHuPH20 (NCT01426763)
- 2012-08-31Results posted on the registry: Pharming Technologies B.V., Recombinant Human C1 Inhibitor + placebo (NCT00225147)
- 2012-08-30Results posted on the registry: Pharming Technologies B.V., recombinant human C1 inhibitor + Placebo (NCT00262301)
- 2011-06-23Results posted on the registry: CSL Behring, C1 Esterase Inhibitor (NCT00292981)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision